

IN THE CLAIMS

Please cancel claims 1-81.

claim 1-61 (previously canceled)

claim 62-81 (canceled)

Please add the following claims::

claim 82 (new) A parenteral therapeutic agent for the treatment of bacterial infections, said parenteral therapeutic agent produced by the method of:

(a) obtaining an effective amount of at least one enzyme genetically coded for by bacteriophage specific for a specific bacteria, wherein said at least one enzyme is selected from the group consisting of lytic enzymes, shuffled lytic enzymes, chimeric lytic enzymes, holin lytic enzymes, and combinations thereof, said at least one enzyme having the ability to digest a cell wall of a specific said bacteria; and,

(b) mixing (a) with a carrier for the parenteral delivery of said at least one lytic enzyme to the site of the infection.

claim 83 (new) The parenteral therapeutic agent according to claim 82, wherein the at least one said enzyme is for the treatment of *Pseudomonas*.

claim 84 (new) The parenteral therapeutic agent according to claim 82, wherein the at least one said

enzyme is for the treatment of *Streptococcus*

claim 85 (new) The parenteral therapeutic agent according to claim 82, wherein the at least one said enzyme is for the treatment of *Staphylococcus*.

claim 86 (new) The parenteral therapeutic agent according to claim 82, wherein said composition further comprises a buffer that maintains pH of the composition at a range between about 4.0 and about 9.0.

claim 87 (new) The parenteral therapeutic agent according to claim 86, wherein the buffer maintains the pH of the composition at the range between about 5.5 and about 7.5.

claim 88 (new) The parenteral therapeutic agent according to claim 86, wherein said buffer comprises a reducing reagent.

claim 89 (new) The parenteral therapeutic agent according to claim 88, wherein said reducing reagent is dithiothreitol.

claim 90 (new) The parenteral therapeutic agent according to claim 86, wherein said buffer

comprises a metal chelating reagent.

claim 91 (new) The parenteral therapeutic agent according to claim 90, wherein said metal chelating reagent is ethylenediaminetetraacetic disodium salt.

claim 92 (new) The parenteral therapeutic agent according to claim 86, wherein said buffer is a citrate-phosphate buffer.

claim 93 (new) The parenteral therapeutic agent according to claim 86, further comprising a bactericidal or bacteriostatic agent as a preservative.

claim 94 (new) The parenteral therapeutic agent according to claim 82, further comprising administering a concentration of about 100 to about 500,000 active enzyme units per milliliter of fluid.

claim 95 (new) The parenteral therapeutic agent according to claim 82, further comprising administering the concentration of about 1000 to about 100,000 active enzyme units per milliliter of fluids.

claim 96 (new) The parenteral therapeutic agent according to claim 82, wherein said therapeutic agent is administered intravenously.

claim 97 (new) The parenteral therapeutic agent according to claim 82, wherein said therapeutic agent is administered intramuscularly.

claim 98 (new) The parenteral therapeutic agent according to claim 82, wherein said therapeutic agent is administered subcutaneously.

claim 99 (new) The parenteral therapeutic agent according to claim 82, wherein the therapeutic agent further comprises at least one complementary agent which potentiates the bactericidal activity of the lysine enzyme, said complementary agent being selected from the group consisting of penicillin, synthetic penicillins bacitracin, methicillin, cephalosporin, polymyxin, cefaclor, Cefadroxil, cefamandole nafate, cefazolin, cefixime, cefmetazole, cefonioid, cefoperazone, ceforanide, cefotanme, cefotaxime, cefotetan, cefoxitin, cefpodoxime proxetil, ceftazidime, ceftizoxime, ceftriaxone, cefriaxone moxalactam, cefuroxime, cephalexin, cephalosporin C, cephalosporin C sodium salt, cephalothin, cephalothin sodium salt, cephapirin, cephadrine, cefuroximeaxetil, dihydratecephalothin, moxalactam, loracarbef, mafate and chelating agents.

claim 100 (new) The parenteral therapeutic agent according to claim 82, wherein said at least one said holin lytic enzyme is a shuffled holin lytic enzyme.

claim 101 (new) The parenteral therapeutic agent according to claim 82, wherein said at least one holin enzyme is a chimeric holin lytic enzyme.

claim 102 (new) The parenteral therapeutic agent according to claim 82, further comprising at least one lytic enzyme which is not selected from the group consisting of at least one shuffled lytic enzyme, chimeric lytic enzyme, and holin lytic enzyme.